The Detection Assay Compound
SLU-PP-332
Also known as Pan-ERR agonist · Exercise mimetic
At a glance
- What it is
- Pan-ERR agonist with no human programme. Its 2026 literature is doping detection.
- Evidence
- Practitioner experience onlyHow the tiers workSLU-PP-332 is confirmed as a small molecule, PubChem CID 5338394, formula C18H14N2O2, and is not a peptide. Why this tier
- Half-life
- Not established in available literature
- Routes
- Oral, Subcutaneous
- Category
- Metabolic
- WADA
- We do not state a status
Not schedulable in Claritide. Our sources publish no dosing figure for SLU-PP-332, so there is nothing to build a schedule from.
Why this tier
SLU-PP-332 is confirmed as a small molecule, PubChem CID 5338394, formula C18H14N2O2, and is not a peptide. There is no human clinical trial programme and no human exposure data. The entire 2026 literature on it is anti-doping metabolite characterisation, with 22 in vitro metabolites identified and papers framed explicitly for doping-control purposes, plus structure-activity optimisation work and an orally active successor compound, SLU-PP-915. No credible human dose exists and we refuse to publish one.
What it is
SLU-PP-332 is a small-molecule agonist of the oestrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, from the Burris laboratory. There is no human clinical trial programme. Its entire 2026 literature is anti-doping metabolite characterisation and medicinal-chemistry optimisation, which tells you that the people paying attention to it professionally are the ones building tests to catch it.
How it works
The oestrogen-related receptors are transcription factors that govern mitochondrial biogenesis and fatty-acid oxidation, much of the transcriptional programme that endurance exercise switches on. SLU-PP-332 activates all three, which is why it is described as an exercise mimetic. The honest framing of that phrase, from the literature itself: it replicates the metabolic signalling of endurance training and does not replicate the mechanical stress of physical movement. Bone loading, tendon adaptation, cardiovascular work and the neuromuscular component of training are not in the package.
Commonly researched ranges
Not established in available literature. Our sources describe SLU-PP-332 without publishing a dosing figure, so Claritide does not print one.
- Cycle guidance
- Not established in available literature
- Goals
- Fat loss, Energy
Where this sits with the FDA
A preclinical research compound with no human clinical programme, no approval anywhere, and no entry on FDA’s compounding lists.
Primary sourceWADA status
We could not verify a WADA classification for SLU-PP-332 and do not state one. What is verified is that anti-doping laboratories are actively building detection assays for it: 22 in vitro metabolites have been characterised in papers framed explicitly for doping-control purposes. Draw the obvious inference about where this is heading, but we will not print a status we cannot source.
We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.
Mixing recipes our sources document
Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator
Week by week
Not established in available literature.
Side effects
Not established in available literature. Absence from this page does not mean absence of risk. It means our sources publish no side-effect profile for SLU-PP-332.
Contraindications and interactions
Do not use if
- No credible human dose exists, so there is no way to use this compound at a dose anyone has justified
Interactions
Not established in available literature.
Absence from this list does NOT mean safety. It means lack of research.
Storage and cost
- Storage
- Our sources publish no handling protocol, because there is no human dosing protocol to handle it for.
- Cost
- Not established in available literature
SLU-PP-332 in full
Limited coverage
SLU-PP-332 is a small molecule, PubChem CID 5338394, formula C18H14N2O2, and not a peptide. It is a potent selective agonist of the oestrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, developed in the Burris laboratory.
What it does, and what "exercise mimetic" actually means
The ERRs are transcription factors controlling mitochondrial biogenesis and fatty-acid oxidation, a large part of the programme endurance training switches on. Activating all three drives that programme pharmacologically.
The literature's own framing is the honest one: it replicates the metabolic signalling of endurance training, but does not replicate the mechanical stress of physical movement. No bone loading, no tendon adaptation, no cardiovascular work, no neuromuscular component. Whatever "exercise in a pill" means, it does not mean exercise.
No human programme
There is no human clinical trial programme and no human exposure data. None.
What there is, in 2026, is anti-doping chemistry. Twenty-two in vitro metabolites have been characterised, in papers framed explicitly for doping-control purposes and describing the compound as having doping potential. There is also medicinal-chemistry optimisation work and an orally active successor compound, SLU-PP-915.
That is a striking asymmetry. The only groups publishing on this molecule in 2026 are the ones designing tests to detect it in athletes, and the ones designing a better version of it. Neither is running a trial in people.
What we will not publish
A dose. There is no credible human dose for SLU-PP-332 and inventing one from a mouse study would be exactly the failure mode this library exists to avoid.
We also do not state a WADA classification, because we could not verify one. What we can say is that laboratories are actively building assays for it, which is not a status but is a fact worth knowing if you are tested.
Sources
- 1PubChem · SLU-PP-332, CID 5338394
- 2Anti-doping metabolite characterisation of SLU-PP-332 (2026)
- 3Further SLU-PP-332 doping-control chemistry (2026)
- 4Structure-activity optimisation and SLU-PP-915 (2026)
Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.